Publications by authors named "Michael Untch"

Claim this Profile
P
Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study.
Xingrong Liu, Behnaz Binicy, Balazs Acs, Louise Eriksson Bergman, Sibylle Loibl, Michael Untch

Lancet Reg Health Eur· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials.
Fabio Conforti, Johannes Holtschmidt, Valentina Nekljudova, Isabella Sala, Eleonora Pagan, Michael Untch

Lancet Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.
Sibylle Loibl, Yeon Hee Park, Zhiming Shao, Chiun-Sheng Huang, Carlos Barrios, Michael Untch

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025.
Toralf Reimer, Thorsten Kuehn, Volkmar Mueller, Nina Ditsch, Tanja Fehm, Michael Untch

Eur J Surg Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.
Peter A Fasching, Daniil Stroyakovskiy, Denise A Yardley, Chiun-Sheng Huang, John Crown, Michael Untch

JAMA Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer.
Laura L Michel, Philipp Ziegler, Philipp Kreis, Andreas D Hartkopf, Markus Wallwiener, Michael Untch

Eur J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: Germline and Somatic Mutations in Breast Cancer Treatment Strategies.
Eric Hahnen, Jan Hauke, Karen Gelmon, Frederik Marmé, Corinna Ernst, Michael Untch

JCO Precis Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Macrophage polarization is associated with postoperative seroma development in breast cancer in the SerMa pilot cohort.
Felicitas Magdalena Schneider, Nicole Pochert, Fritzi Schittek, Melitta Beatrice Köpke, Carl Mathis Wild, Michael Untch

Sci Rep· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ribosomal RNA Degradation (RNA Disruption) in Tumour Cells: Mechanistic Insights and Potential Clinical Utility.
Amadeo M Parissenti, Sanaa Noubir, Laura B Pritzker, Thomas Kovala, Carita Lannér, Michael M Untch

Cancers (Basel)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Patients with Early Breast Cancer: 19th St. Gallen International Breast Cancer Consensus Discussed against the Background of German Treatment Recommendations.
Michael Untch, Maggie Banys-Paluchowski, Sara Y Brucker, Carsten Denkert, Peter A Fasching

Geburtshilfe Frauenheilkd· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2- early breast cancer.
Wolfgang Janni, Michael Untch, Nadia Harbeck, Joseph Gligorov, William Jacot

Breast· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indirect Treatment Comparison between Ribociclib Combined with Non-Steroidal Aromatase Inhibitors and Ovarian Function Suppression vs. Tamoxifen in Premenopausal Women with Early Breast Cancer.
Diana Lüftner, Maggie Banys-Paluchowski, Andreas D Hartkopf, Manuel Hörner, Wolfgang Janni, Michael Untch

Geburtshilfe Frauenheilkd· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radar reflectors for marking of target lymph nodes in initially node-positive patients receiving neoadjuvant chemotherapy for breast cancer-a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial.
Maggie Banys-Paluchowski, Steffi Hartmann, Timo Basali, Maria Luisa Gasparri, Jana de Boniface, Michael Untch

Breast Cancer Res Treat· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study.
Peter A Fasching, Sabine Schmatloch, Jan Hauke, Julia Rey, Christian Jackisch, Michael Untch

Clin Cancer Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.
Peter A Fasching, Dennis Slamon, Zbigniew Nowecki, Bozena Kukielka-Budny, Daniil Stroyakovskiy, Michael Untch

Clin Cancer Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update Breast Cancer 2024 Part 2 - Patients with Early Stage Breast Cancer.
Wolfgang Janni, Hans-Christian Kolberg, Andreas D Hartkopf, Tanja N Fehm, Manfred Welslau, Michael Untch

Geburtshilfe Frauenheilkd· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update Breast Cancer 2024 Part 3 - Patients with Advanced Stage Breast Cancer.
Diana Lüftner, Hans-Christian Kolberg, Andreas D Hartkopf, Tanja N Fehm, Manfred Welslau, Michael Untch

Geburtshilfe Frauenheilkd· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer.
Fabio Conforti, Valentina Nekljudova, Isabella Sala, Roberto Ascari, Christine Solbach, Michael Untch

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer.
Christina B Walter, Andreas D Hartkopf, Alexander Hein, Peter A Fasching, Hans-Christian Kolberg, Michael Untch

Breast· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis.
Eric Hahnen, Jan Hauke, Karen Gelmon, Frederik Marmé, Corinna Ernst, Michael Untch

JCO Precis Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2025.
Tjoung-Won Park-Simon, Volkmar Müller, Ute-Susann Albert, Maggie Banys-Paluchowski, Rupert Bartsch, Michael Untch

Breast Care (Basel)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2025.
Marc Thill, Wolfgang Janni, Ute-Susann Albert, Maggie Banys-Paluchowski, Rupert Bartsch, Michael Untch

Breast Care (Basel)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping.
Carsten Denkert, Sivaramakrishna Rachakonda, Thomas Karn, Karsten Weber, Miguel Martin, Michael Untch

Cancer Cell· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.
Charles E Geyer, Michael Untch, Chiun-Sheng Huang, Max S Mano, Eleftherios P Mamounas

N Engl J Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers.
Lothar Häberle, Ramona Erber, Paul Gass, Alexander Hein, Melitta Niklos, Michael Untch

Breast Cancer Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis